Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Yahoo Finance5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
Business Insider6d
GSK Pharma put volume heavy and directionally bearish
Bearish flow noted in GSK (GSK) Pharma with 2,296 puts trading, or 1.2x expected. Most active are May-25 30 puts and Dec-24 38 calls, with total volume in those strikes near 2,500 contracts.
ARY News Live6d
Arexvy: Canada approves GSK’s RSV vaccine
Reuters is an international news organisation owned by Thomson Reuters GSK has received Canadian approval for Arexvy, its respiratory syncytial virus vaccine in adults between 50 and 59 ...
The Pharma Letter5d
GSK’s Arexvy receives expanded approval in Canada
GSK’s (LSE: GSK) Arexvy (RSV vaccine) has received an expanded approval in Canada to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 50-59 who are at ...
infectiousdiseaseadvisor.com6d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
pharmaphorum6d
GSK gets EU okay for RSV shot in younger age group
GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...